drmolander.com

Genome and microbiome – how body data becomes a strategy for longevity

admin — Wed, 13 May 2026 10:51:27 +0000

Dr. Molander was invited by Forbes Bulgaria to speak via an interview with Boryana Gerasimova , founder and CEO of Re:Gena, Dr. Molander discusses, "Genome and microbiome - how body data becomes a strategy for longevity."

The event takes place on June 11, 2026 and brings together physicians, researchers, entrepreneurs, and health leaders exploring the future of longevity medicine, prevention, cognitive health, cardiovascular care, stress physiology, regenerative medicine, and personalized health strategies.

Other featured participants include neurologist Lachezar Traykov (rector of the Medical University of Sofia) discussing cognitive longevity, cardiologist Arman Postadjiyan on cardiovascular health and aging, and specialists in psychiatry, endocrinology, regenerative medicine, aesthetics, and metabolic health. Dr. Molander’s participation reflects the growing interest in nutrigenomics, microbiome science, and individualized medicine as part of the broader longevity conversation.

The post Genome and microbiome – how body data becomes a strategy for longevity appeared first on drmolander.com.

My hormones are ‘normal’ — So why do I feel so off?

admin — Thu, 05 Mar 2026 13:53:25 +0000

Most of us are taught to think about hormones as “levels.” High or low. Balanced or unbalanced. This model is not wrong. It is incomplete.

Hormone symptoms are not only about what your body makes. They are also about what your body is able to move out.

That’s the missing half of hormone symptoms. And once you see it, the mismatch between “normal labs” and real symptoms starts to make more sense.

If you feel hormonally off even though your results are “normal,” the usual explanation may be stopping too early. There is often a reason why you feel tired, wired, moody, swollen, restless, or unable to predict how you will feel from one week to the next.

What gets missed is simple: “normal” can describe a number, but not the whole story.

Normal labs vs real symptoms

Think of it this way: a blood test is a snapshot, a photograph. Your symptoms are a pattern over time.

This is one reason lab results can look normal and, yet, you feel “off.” Which means the real question is not “What is the number today?” The better question is, “What has my body been doing over time?”

Hormone symptoms change with context. Sleep, stress load, digestion, and blood sugar rhythm can shift how you feel—sometimes more than you expect. And in perimenopause, that variability can be more pronounced.

What gets missed is simple: when we treat the snapshot as the whole story, we stop looking for the missing half.

And that missing half is not only what your body makes. It is also what it is able to move out.

What ‘move out’ means

When I say “move out,” I mean what happens after hormones have done their job.

Your body has to process them, package them, and guide them out of your system. If this last part is not working smoothly, you can feel hormonally “off” even when a lab value looks normal.

Think of the loop like this: it is not finished when hormones are made. It is finished when your body is able to move them out reliably.

If your sleep is poor, digestion slows down and bowel rhythm becomes irregular. When this happens many women experience stronger and less predictable symptoms. The number may not change much but pattern does.

Where hormones leave the body

One of the main ways hormones leave the body is through the gut. No, the gut is not the only factor, yet it is an important part of the exit route. The body processes hormones, packages them, sends them into the digestive tract, and then moves them out through the stool.

How you feel is not only a “hormone problem.” It can be a digestion, bowel rhythm, sleep, stress, or blood sugar stability problem.

You see, this often gets missed. These are not separate stories. They are part of the same loop.

Think of it in simple terms: when the body is not moving waste out well, you feel the effects. The same pattern can show up here. When digestion slows and bowel rhythm becomes irregular, many women notice hormone symptoms feel more intense, less predictable and harder to correct.

The missing piece

This is where you might get confused. Stay with me. If symptoms feel stronger, or more difficult to correct, the natural assumption is hormone levels themselves must be high, low, or wildly unstable.

Sometimes that is true. What gets missed is symptom intensity is not always coming from production alone. It can also reflect how well the loop is finishing.

Which means two women can have similar lab results and still feel very different.

One woman may move hormones through and out of the body more smoothly. Another may be dealing with slower digestion, less regular bowel rhythm, poorer sleep, higher stress load, or a more reactive system overall. The lab value may look similar. The lived experience may not.

This is one reason some women feel persistently “hormonal” even when the numbers do not clearly explain why. Symptoms can feel louder, stick around longer and become harder to predict.

That does not mean your symptoms are exaggerated. It does not mean you are becoming fragile. And it does not mean the lab was useless.

It means the number may be real, but the explanation is incomplete.

Look at the pattern

I want you to ask yourself: are your symptoms pointing mainly to what your body is making? Or are they pointing to how well your body is handling and moving hormones out?

This is not a diagnosis. It is a more useful way to start thinking.

Let's say symptoms follow a fairly consistent pattern. They come during the same part of the cycle, similar timing, similar shape each month. That may point more toward production, timing, or signaling.

If symptoms feel more amplified after poor sleep, constipation, travel, stress, irregular eating, or periods of digestive slowdown, that may point more toward the other half of the story.

And in perimenopause, the two can overlap. Which means the picture can look less neat.

This is why it helps to stop asking only, “Are my hormones normal?” and start asking, “What pattern is my body showing me?”

That shift does not solve the problem by itself. But it often changes what deserves attention next.

See the bigger story

Once you stop looking at hormone symptoms as a number-only problem, the next step becomes more precise.

Instead of asking only whether a hormone level is high or low, we start asking what else may be shaping the pattern. Sleep. Digestion. Bowel regularity. Stress load. Blood sugar rhythm. Daily habits. Medication context. Perimenopause itself.

Which means the goal is not to chase symptoms from one hormone to the next. The goal is to understand the conditions under which your symptoms become louder, more reactive, or harder to settle.

This is also where sequencing matters.

Because if the wider pattern is being missed, it is easy to focus too narrowly or too early on the hormone itself, while overlooking the physiology that may be shaping how that hormone is felt.

That does not mean hormones do not matter. It means they are often part of a bigger story.

And that bigger story is usually where the next useful clue lives.

For many women, this is the point where the picture widens again.

Because once the hormone loop becomes less stable, the whole system can begin to feel more reactive. Sleep loss hits harder. Stress feels less recoverable. Digestion becomes more sensitive. Blood sugar swings feel more disruptive.

Which means you may start to feel like your body is overreacting to everything.

What gets missed is this pattern is not random. And it is not a personality flaw. It is often a sign your whole system has become easier to push off balance. That is a related map of its own. And an important one.

A new way to understand what’s happening

If you have been told your hormone labs are “normal” but you still feel clearly off, you are not imagining it.

A normal result can be real. And the explanation can still be incomplete.

Because hormone symptoms are not only about what your body makes. It’s not just what you make. It’s what your body can move out.

When you start looking for the full loop, your symptoms become easier to interpret. And the next steps become more precise.

The post My hormones are ‘normal’ — So why do I feel so off? appeared first on drmolander.com.

A Colorectal Cancer 3D Bioprinting Workflow as a Platform for Disease Modeling and Chemotherapeutic Screening

admin — Tue, 09 Dec 2025 06:58:34 +0000

My colleagues and I present a simple, highly reproducible, and flexible 3D bioprinted model of CRC which resembles certain aspects of the cells closer than conventional 2D cultures. We validated our workflow as a template for testing the response to chemotherapeutics. Therefore, this novel in vitro model has the potential to become a useful experimental platform for future fundamental and preclinical studies directed to personalized medicines.

The abstract and analysis are available here.

The post A Colorectal Cancer 3D Bioprinting Workflow as a Platform for Disease Modeling and Chemotherapeutic Screening appeared first on drmolander.com.

Implication of LAMP proteins and autophagy markers in colorectal cancer aggressiveness

admin — Tue, 09 Dec 2025 06:49:29 +0000

To date, no prior studies have investigated the expression of LAMPs in relation to tumor budding and autophagy in CRC. Therefore, we are the first to demonstrate moderate to strong expression of LAMP1, LAMP2 and LAMP2A in the tumor stroma and front in CRC tissues. The significant association between the expression of these proteins and the tumor budding indicates their implication in cancer cells’ invasiveness.

Our results demonstrate that all the three major forms of autophagy might be activated in our CRC group.

However, our study has its limitations. The analysis sample is modest, which could explain some of the null associations observed. Future validation studies are needed to test the robustness of our findings. The limited sample size resulted in insufficient statistical power for exploring the potential effect modifiers at different stages of CRC progression (as stage II vs III/IV). However, since CRC is a highly heterogeneous disease stratified analyses could have revealed associations that may have been obscured in the total sample group. Another limitation is that the study is exploratory and correlational, providing only suggestive evidence of causality. Actual experimental manipulation in CRC models would provide stronger mechanistic evidence.

Access the abstract and full analysis here.

The post Implication of LAMP proteins and autophagy markers in colorectal cancer aggressiveness appeared first on drmolander.com.

European Association for Cancer Research – Diana Molander

admin — Mon, 01 Dec 2025 16:57:12 +0000

At the Annual Congress of the European Association for Cancer Research, held on June 16-19, 2025, in Lisbon, Portugal, Dr. Molander presented results related to the efficacy of classic therapeutic regimens combined with natural products on 3D bioprinted colorectal cells.

Colorectal cancer (CRC) is the second leading cause of all cancer-related deaths worldwide. The incidence of CRC is increasing by 1 to 2% annually and is rising dramatically among the younger population. The poor prognosis is partly due to the resistance to chemotherapy acquired by tumor cells.

Numerous studies demonstrate that the consumption of soy and soy products is beneficial to human health. The biological activity of soy products is due to the presence of isoflavones in soy. In the human intestinal tract, specific bacteria have the ability to metabolize soy isoflavones into a metabolite with anti-cancer properties.

The biological effects of soy isoflavones and their metabolites on various types of cancer, including CRC, have been studied intensively in recent years. 3D bioprinted tumor models resemble primary tumors morphologically and biochemically and serve as platforms for drug testing.

A number of studies in recent years have demonstrated that consumption of soy products reduces the risk of developing various diseases.

Team: Diana Molander, Tsvetomira Ivanova, Yordan Sbirkov, Victoria Sarafian

The post European Association for Cancer Research – Diana Molander appeared first on drmolander.com.

European Association for Cancer Research (2025)

Diana Molander — Sat, 08 Nov 2025 20:10:26 +0000

Personalized nutrition based on genes and gut health as part of any therapeutic approach.

Conference program.

1. Core Thesis

There is no perfect diet.
Effective nutrition must be personalized, integrating genetic potential (DNA) with current physiological reality (gut microbiome).

Universal dietary advice fails because it ignores biological diversity, gene–nutrient interactions, and microbial context. Personalized nutrition is positioned not as a lifestyle trend, but as a clinical necessity.

2. Why Universal Dietary Advice Fails

Standard recommendations such as “eat less, move more” oversimplify health and shift responsibility onto willpower, while overlooking:

Genetic variability
Metabolic differences
Microbiome-mediated responses
Environmental stressors

Consequence

Patients often experience:

Repeated diet failure
Confusion from contradictory advice
Harm from influencer-driven, non–biology-matched diets

This reframes diet failure as physiological mismatch, not lack of discipline.

3. Modern Context: Nutrition in 2025

Citing contemporary thought (e.g. Justin Harris), the presentation describes today’s environment as:

Excess calories, mostly ultra-processed
Extreme information noise, amplified by social media
Choice paralysis caused by too many mutually exclusive dietary models

Key Reframe

Food is presented as an epigenetic signal:

Every meal sends instructions to the body with lasting biological effects.

Implication:
Personalization is no longer optional—it is a survival strategy in an overprocessed, over-informed food landscape.

4. Nutrigenetics & Nutrigenomics: The Scientific Foundation

Nutrigenetics

Genetic variants (SNPs) influence how individuals:

Absorb nutrients
Convert nutrients
Metabolize macronutrients and micronutrients

Example:

BCMO1 gene: Some individuals poorly convert beta-carotene → vitamin A
These individuals require preformed retinol, not plant carotenoids

Nutrigenomics

Nutrients themselves influence:

Gene expression
Inflammatory pathways
Long-term health outcomes

Key Principle

The gene–nutrition relationship is bidirectional:

Genes shape nutritional needs
Nutrition reshapes gene expression

This directly challenges dietary dogma and justifies a precision-based approach.

5. DNA in Personalized Nutrition

DNA testing provides insight into:

Carbohydrate, fat, and vitamin metabolism
Risk predispositions (e.g. insulin resistance, lactose intolerance, inflammatory tendencies)
Nutritional strategies aligned with genetic ability rather than ideology

DNA defines potential and constraints, not destiny.

6. The Gut Microbiome: The Dynamic Half of the Equation

Unlike DNA, the microbiome is modifiable and responsive.

Role of the Microbiome

Nutrient breakdown & absorption
Vitamin synthesis
Immune modulation
Metabolic and even neurobehavioral influence

Dysbiosis Consequences

Malabsorption
Chronic inflammation
Poor dietary response despite “correct” nutrition

Clinical Case Logic

Microbiome testing → targeted probiotics/prebiotics/dietary changes → symptom reversal within ~6 weeks.

Key distinction:
DNA is static. The microbiome is adaptive.

7. From Knowledge to Clinical Application

Foundational Clinical Rules

Interpret patterns, not individual organisms
Marker levels must be contextualized with:
- Symptoms
- Stool chemistry
- Diet
- Inflammatory markers
Avoid treating single microbes in isolation

This prevents reductionist errors and unnecessary interventions.

8. Case Example: Microbial Pattern Interpretation (Table Overview)

The referenced table illustrates pattern-based decision-making, not organism eradication.

Examples:

Faecalibacterium prausnitzii
- Low: inflammatory risk, barrier weakness
- High: carb overload or maldigestion
- Intervention focuses on cross-feeding and anti-inflammatory substrates, not suppression
Akkermansia muciniphila
- Low: metabolic dysfunction
- High: possible neuro-inflammatory associations
- Strategy differs based on context and functionality
Methanogens
- High: IBS-C, slowed motility
- Low: inflammatory vulnerability
- Interventions adjust fermentation and energy flux
Fusobacterium spp.
- High: systemic inflammatory associations
- Strategy emphasizes oral–gut axis and polyphenol modulation

The emphasis remains consistent: context > presence.

9. Reframing Diet Failure

A central psychological and clinical insight:

Diet failure is rarely about willpower.

DNA and microbiome data reveal:

Neurochemical drivers of appetite
Microbial influences on cravings and tolerance
Structural reasons certain diets predictably fail for specific individuals

This shift reduces patient blame and increases clinical precision.

10. Final Takeaway

The presentation advances a clear hierarchy:

Universal diets fail
Genes define capacity
Microbiome defines current response
Functional testing bridges science and application
Clinical personalization replaces dietary ideology

Personalized nutrition is framed as evidence-based, clinically grounded, and biologically respectful—not trendy, not permissive, and not motivational rhetoric.

The post European Association for Cancer Research (2025) appeared first on drmolander.com.

International Academy of Medical Innovation and Science

Diana Molander — Sat, 08 Nov 2025 20:05:51 +0000

Lecture Title: Personalized nutrition based on genes and gut health as part of any therapeutic approach.

Conference program.

1. Core Thesis

There is no perfect diet.
Effective nutrition must be personalized, integrating genetic potential (DNA) with current physiological reality (gut microbiome).

2. Why Universal Dietary Advice Fails

Standard recommendations such as “eat less, move more” oversimplify health and shift responsibility onto willpower, while overlooking:

Genetic variability
Metabolic differences
Microbiome-mediated responses
Environmental stressors

Consequence

Patients often experience:

Repeated diet failure
Confusion from contradictory advice
Harm from influencer-driven, non–biology-matched diets

This reframes diet failure as physiological mismatch, not lack of discipline.

3. Modern Context: Nutrition in 2025

Citing contemporary thought (e.g. Justin Harris), the presentation describes today’s environment as:

Excess calories, mostly ultra-processed
Extreme information noise, amplified by social media
Choice paralysis caused by too many mutually exclusive dietary models

Key Reframe

Food is presented as an epigenetic signal:

Every meal sends instructions to the body with lasting biological effects.

Implication:
Personalization is no longer optional—it is a survival strategy in an overprocessed, over-informed food landscape.

4. Nutrigenetics & Nutrigenomics: The Scientific Foundation

Nutrigenetics

Genetic variants (SNPs) influence how individuals:

Absorb nutrients
Convert nutrients
Metabolize macronutrients and micronutrients

Example:

BCMO1 gene: Some individuals poorly convert beta-carotene → vitamin A
These individuals require preformed retinol, not plant carotenoids

Nutrigenomics

Nutrients themselves influence:

Gene expression
Inflammatory pathways
Long-term health outcomes

Key Principle

The gene–nutrition relationship is bidirectional:

Genes shape nutritional needs
Nutrition reshapes gene expression

This directly challenges dietary dogma and justifies a precision-based approach.

5. DNA in Personalized Nutrition

DNA testing provides insight into:

Carbohydrate, fat, and vitamin metabolism
Risk predispositions (e.g. insulin resistance, lactose intolerance, inflammatory tendencies)
Nutritional strategies aligned with genetic ability rather than ideology

DNA defines potential and constraints, not destiny.

6. The Gut Microbiome: The Dynamic Half of the Equation

Unlike DNA, the microbiome is modifiable and responsive.

Role of the Microbiome

Nutrient breakdown & absorption
Vitamin synthesis
Immune modulation
Metabolic and even neurobehavioral influence

Dysbiosis Consequences

Malabsorption
Chronic inflammation
Poor dietary response despite “correct” nutrition

Clinical Case Logic

Microbiome testing → targeted probiotics/prebiotics/dietary changes → symptom reversal within ~6 weeks.

Key distinction:
DNA is static. The microbiome is adaptive.

7. From Knowledge to Clinical Application

Foundational Clinical Rules

Interpret patterns, not individual organisms
Marker levels must be contextualized with:
- Symptoms
- Stool chemistry
- Diet
- Inflammatory markers
Avoid treating single microbes in isolation

This prevents reductionist errors and unnecessary interventions.

8. Case Example: Microbial Pattern Interpretation (Table Overview)

The referenced table illustrates pattern-based decision-making, not organism eradication.

Examples:

Faecalibacterium prausnitzii
- Low: inflammatory risk, barrier weakness
- High: carb overload or maldigestion
- Intervention focuses on cross-feeding and anti-inflammatory substrates, not suppression
Akkermansia muciniphila
- Low: metabolic dysfunction
- High: possible neuro-inflammatory associations
- Strategy differs based on context and functionality
Methanogens
- High: IBS-C, slowed motility
- Low: inflammatory vulnerability
- Interventions adjust fermentation and energy flux
Fusobacterium spp.
- High: systemic inflammatory associations
- Strategy emphasizes oral–gut axis and polyphenol modulation

The emphasis remains consistent: context > presence.

9. Reframing Diet Failure

A central psychological and clinical insight:

Diet failure is rarely about willpower.

DNA and microbiome data reveal:

Neurochemical drivers of appetite
Microbial influences on cravings and tolerance
Structural reasons certain diets predictably fail for specific individuals

This shift reduces patient blame and increases clinical precision.

10. Final Takeaway

The presentation advances a clear hierarchy:

Universal diets fail
Genes define capacity
Microbiome defines current response
Functional testing bridges science and application
Clinical personalization replaces dietary ideology

Personalized nutrition is framed as evidence-based, clinically grounded, and biologically respectful—not trendy, not permissive, and not motivational rhetoric.

The post International Academy of Medical Innovation and Science appeared first on drmolander.com.

Fatty liver is not a liver problem

Diana Molander — Sat, 08 Nov 2025 19:58:12 +0000

Fatty liver disease is usually discovered by accident. A mildly elevated ALT. An ultrasound ordered for something else. A comment added almost in passing: “You have some fat in the liver.”

From there, the script is familiar. Lose weight. Exercise more. Cut sugar. Come back in six months.

This approach assumes the liver is where the problem begins. But it isn’t.

Why fatty liver is misdiagnosed from the start

Standard evaluation shows where fat accumulates, not why it stays there, and not what the liver is exposed to upstream. That distinction matters. Accumulation and exposure follow different logic.

If fatty liver were a storage problem, weight loss would resolve it. Sometimes it does. Often, it doesn’t. That inconsistency is usually explained as non-compliance or bad luck. In reality, it reflects a diagnostic failure.

The tools used are blunt by design.

Liver enzymes rise after damage has occurred. Levels often normalize even as inflammation and fibrosis continue. Biopsy-based studies confirm persistent liver injury despite normal ALT and AST.

The signal quiets. The process continues.

Imaging adds limited clarity. It shows fat. Sometimes stiffness. It does not show inflammatory signals entering through the portal vein. It does not show whether fat export has recovered. Even fibrosis scores describe outcome, not origin.

So improvement is inferred from markers known to lag behind disease activity.

That gap is structural, not accidental.

The liver’s real role (and why it gets blamed)

The liver is not an origin organ. It is a processing organ.

Everything absorbed from the gut reaches the liver first through portal circulation. Nutrients. Metabolic byproducts. Bacterial fragments. Immune signals. The liver processes whatever arrives. It does not choose the input.

When fat appears in liver tissue, it is assumed the liver created the problem. More often, the liver is responding to volume and composition arriving from upstream.

The liver performs active tasks. It packages fat for export. It neutralizes toxins. It regulates immune responses. Each task demands energy and capacity.

When upstream input shifts toward inflammatory exposure, the liver adapts.

Portal circulation ensures concentration. Gut-derived products reach the liver before dilution elsewhere in the body. Protective mechanisms exist. They are finite.

Fat accumulation is not a mistake. It is an adaptive response. Storing fat reduces immediate lipotoxic exposure. Dampening immune signaling prevents systemic escalation.

These strategies carry a cost.

As exposure continues, export slows. Defense takes priority. Scar tissue replaces flexible tissue.

The liver shows damage because it stands first in line.

Blame follows visibility.

Failure #1: Barrier breakdown

Exposure, not fat.

The gut is a barrier. Its role is selective entry. Nutrients pass through. Biologically active fragments remain contained. In fatty liver disease, this control weakens.

Human studies consistently show increased intestinal permeability in MASLD. Circulating levels of lipopolysaccharide rise in parallel. Both correlate with disease severity.

LPS acts as an immune alarm. It enters portal circulation repeatedly and predictably.

Hepatic immune cells recognize LPS through toll-like receptors. The response is appropriate for acute infection. With chronic exposure, the same pathway produces inflammation and fibrotic signaling. Stellate cells activate. Tissue architecture changes.

This process appears early. Elevated permeability and endotoxin markers precede advanced fibrosis, cirrhosis, and dramatic enzyme elevation.

Calling this “leaky gut” understates the mechanism. The problem is loss of control, not random leakage.

Persistent exposure shifts liver priorities. Defense overrides export. Fat accumulates in that context.

Weight loss may reduce load. It does not automatically remove exposure.

Until barrier integrity improves, downstream interventions struggle.

Failure #2: Metabolic blockade

Why fat can’t leave.

Fat leaves the liver through active export. The liver packages fat into VLDL particles and releases them into circulation. That process depends on adequate choline availability.

Choline deficiency and impaired VLDL export

Choline is structural. Without it, VLDL assembly slows. Fat remains inside hepatocytes.

Gut microbiology influences whether choline reaches the liver.

Specific bacterial groups convert dietary choline into methylamines before absorption. In individuals enriched in these microbes, effective choline availability drops despite sufficient intake.

Human and mechanistic studies link this diversion to impaired fat export and hepatic steatosis.

This is not excess intake. It is impaired trafficking.

When export slows, fat-laden cells become more sensitive to oxidative stress and inflammatory signaling. Steatosis persists even as weight decreases.

Calorie reduction does not correct this bottleneck.

Failure #3: Inflammatory amplification

How liver inflammation becomes systemic

Inflammation in the liver does not remain local.

Activated liver cells release cytokines into circulation. These signals affect insulin sensitivity, vascular function, and immune tone across the body.

MASLD tracks closely with cardiovascular disease because hepatic inflammation amplifies metabolic risk. The relationship is mechanistic, not associative.

Neuroinflammatory effects follow similar signaling pathways. Chronic metabolic inflammation alters blood–brain barrier signaling and cerebral glucose handling. Cognitive and mood effects emerge long before end-stage liver disease.

Amplification begins early.

MASLD often drives systemic dysfunction. It is not merely a downstream consequence.

Why conventional advice sometimes works (often doesn’t)t

Many patients do what they are told. They lose weight. Reduce sugar. Exercise. Numbers improve. Then progress stalls. Imaging lags. Enzymes fluctuate. Frustration follows.

When interventions succeed, they do so indirectly. They improve microbiome composition, barrier function, or export capacity alongside visible change.

When they fail, at least one upstream failure persists.

Compliance is not the variable. Response is.

Why weight loss alone fails in fatty liver disease

Two individuals follow similar plans. One improves consistently. The other plateaus. Without upstream assessment, care repeats itself.

The question shifts.

Not: “Why isn’t this working?”But: “Which upstream failure remains unaddressed?”

Testing Gap: What’s measured vs what drives disease

Most fatty liver workups measure outcomes.

ALT and AST rise with cell injury. They often normalize while inflammation and fibrosis persist. Studies confirm ongoing histologic damage despite improved labs.

Normalization creates diagnostic quiet.

Imaging shows fat and stiffness. It cannot detect immune signaling, endotoxin exposure, or export capacity.

Fibrosis staging describes history. It does not identify drivers.

Barrier function, microbial metabolism, and inflammatory signaling shape trajectory. Those variables rarely appear in standard assessment.

Patients sense the gap because they experience it.

Therapeutic implications

Effective intervention aligns with failure points.

Reducing exposure matters.Restoring export capacity matters.Calming amplification matters.

Lifestyle interventions help only when they correct those mechanisms.

Effort alone does not guarantee alignment.

The reframe

Fatty liver marks where consequences appear, not where problems begin. Engaging differently means questioning measurement.

Were causes explored or outcomes described?Was improvement confirmed or inferred?Was silence mistaken for resolution?

These questions do not reject conventional care. They refine it.

Change what reaches the liver. The response follows.

The post Fatty liver is not a liver problem appeared first on drmolander.com.

The Real Story Behind “Leaky Gut”

Diana Molander — Sat, 08 Nov 2025 19:55:21 +0000

"Leaky gut" sounds like pseudoscience.

It's not.

The scientific term is "increased intestinal permeability." And it's a measurable, clinical entity that drives multiple diseases.

But there's massive confusion. Dubious supplement companies have hijacked the term. That doesn't make the mechanism fake.

What intestinal permeability actually is

Your gut lining is one cell thick. Between these cells are tight junctions—protein complexes that act as gatekeepers.

They decide what enters your bloodstream and what stays in your intestines.

When these junctions malfunction, they open. Bacterial fragments, undigested food proteins, and toxins leak through.

This isn't a disease itself. It's a pathophysiological state. A broken gate that enables disease.

The zonulin pathway: The master switch

Research has identified the molecular mechanism controlling intestinal permeability: zonulin.

Zonulin is "the only physiological modulator of intercellular tight junctions described so far."

Here's how it works:

Triggers: Gliadin (from gluten) or bacterial components bind to receptors on intestinal cells
Release: This triggers zonulin secretion
Signal cascade: Zonulin activates receptors that cause tight junctions to disassemble
Permeability increases: The spaces between cells open

This pathway is physiological. Your body uses it to flush out bacteria from the small intestine by allowing water in.

But in susceptible people, this pathway becomes dysregulated. The gates stay open too long.

The gluten connection (even if you're not celiac)

Here's the part most people miss:

Gliadin increases intestinal permeability in EVERYONE. Not just people with celiac disease.

Studies show gliadin "rapidly and temporarily enhances zonulin-dependent paracellular permeability of the gut, regardless of disease status."

In healthy people, this is temporary and harmless.

In susceptible individuals, repeated exposure creates a chronic problem. Each exposure opens the gate. Each opening allows inflammatory triggers to enter.

This explains non-celiac wheat sensitivity. It's real. It's measurable. It's zonulin-mediated.

Which diseases are linked?

Elevated zonulin (indicating increased permeability) appears in:

Celiac disease and Type 1 diabetes
Inflammatory bowel disease (IBD and IBS)
Autoimmune diseases (lupus, multiple sclerosis, rheumatoid arthritis)
Type 2 diabetes and obesity
Myalgic encephalomyelitis/chronic fatigue syndrome
Migraine
Chronic urticaria (hives)

This doesn't mean leaky gut "causes" all these conditions. But it's a gateway mechanism. It allows the triggers through.

How this drives systemic disease

Once the barrier is compromised:

Bacterial LPS enters: Lipopolysaccharide from gut bacteria crosses into the bloodstream
Liver inflammation: LPS travels directly to the liver via the portal vein, driving fatty liver disease
Immune activation: The immune system attacks these foreign molecules
Food reactions: Undigested proteins trigger food sensitivities
Chronic inflammation: The immune system stays on high alert

This explains why healing the gut is foundational. Until the barrier is restored, inflammation persists.

The SCFA-permeability connection

Short-chain fatty acids (especially butyrate) serve two critical functions:

They're the primary fuel for intestinal cells
They strengthen tight junctions

When beneficial bacteria decline, SCFA production drops. Without enough fuel, intestinal cells weaken. Tight junctions fail.

This creates a vicious cycle:

Dysbiosis reduces SCFAs
Low SCFAs weaken the barrier
A weak barrier allows more dysbiosis

What actually works

The solution isn't random supplements marketed for "leaky gut."

It's identifying and addressing the root causes:

Remove chronic triggers (if gluten is one, remove it)
Restore beneficial bacteria that produce SCFAs
Provide the nutrients intestinal cells need to repair
Reduce inflammation that keeps the barrier compromised

This requires testing. Not guessing.

The bottom line

Increased intestinal permeability is real. The science is solid. The mechanism is understood.

But it's not a diagnosis. It's a dysfunction that underlies many diagnoses.

Think of it as the broken lock that lets disease walk through your front door.

Fix the lock. The intruders can't get in.

The post The Real Story Behind “Leaky Gut” appeared first on drmolander.com.

How Your Gut Bacteria Control Your Mood

Diana Molander — Sat, 08 Nov 2025 19:51:52 +0000

Your gut and brain are in constant conversation.

Most people don't know this. They think depression is "all in your head." It's not.

New research reveals that the gut microbiome plays a fundamental role in regulating mood, anxiety, and stress response. This isn't correlation. It's causation.

The gut-brain axis explained

Your gut and brain communicate through three highways:

The vagus nerve (direct neural connection)
The immune system (inflammatory signals)
Metabolites (chemical messengers in your blood)

When your gut is healthy, these signals promote calm, focus, and resilience.

When your gut is dysbiotic? The signals turn inflammatory and depressive.

What the research shows

Studies consistently find that patients with depression and anxiety have:

Reduced microbial diversity
Significantly lower production of short-chain fatty acids (SCFAs)
Increased systemic inflammation
Elevated pro-inflammatory cytokines

This pattern holds across major depressive disorder, anxiety disorders, and stress-related conditions.

The SCFA connection

Short-chain fatty acids—particularly butyrate—are the key.

These molecules cross the blood-brain barrier and directly influence brain function. They:

Regulate microglial cells (your brain's immune system)
Support the production of BDNF (brain-derived neurotrophic factor)
Reduce neuroinflammation
Modulate neurotransmitter production

When SCFA production drops, neuroinflammation rises. Your brain's immune cells become hyperactive. This drives depressive symptoms.

Think of it as a metabolic deficiency disease. Your brain isn't getting the anti-inflammatory signals it needs to stay balanced.

The neurotransmitter factor

Your gut bacteria produce and modulate:

Serotonin (mood, sleep, appetite)
GABA (calm, reduced anxiety)
Dopamine (motivation, pleasure)
Glutamate (learning, memory)

About 90% of serotonin is produced in the gut. Not the brain.

Specific bacteria are responsible:

Bifidobacterium infantis regulates tryptophan (serotonin's precursor)
Lactobacillus species produce GABA
Various strains influence dopamine pathways

When these beneficial bacteria decline, neurotransmitter balance collapses.

Why anxiety and heart disease often occur together

Here's something surprising: patients with coronary artery disease and depression share the same dysbiotic pattern.

Both groups show:

Increased Staphylococcus and E. coli
Decreased Prevotella, Lactobacillus, and Faecalibacterium
Chronic inflammation
Metabolic abnormalities in SCFA production

This suggests both conditions may stem from the same root dysfunction: a compromised gut producing inflammatory signals instead of protective ones.

What this means clinically

Treating depression solely with psychiatric medication misses a massive piece. If the gut remains dysbiotic, the inflammatory signals continue.

Emerging interventions—called "psychobiotics"—target the microbiome:

Specific probiotic strains shown to reduce anxiety
Prebiotics that feed SCFA-producers
Dietary changes that restore microbial balance

The evidence for these approaches is growing. Clinical trials show measurable improvements in depressive and anxiety symptoms.

The practical takeaway

If you're struggling with mood issues that don't fully respond to conventional treatment, ask: "What's happening in my gut?"

The research is clear. Your gut bacteria influence:

How your brain responds to stress
Whether inflammation becomes chronic
Your production of mood-regulating neurotransmitters
How well your brain's immune system functions

Fixing the gut doesn't replace psychiatric care. But ignoring it may explain why some treatments fail.

Your mood isn't just psychological. It's biological. And much of that biology lives in your gut.

The post How Your Gut Bacteria Control Your Mood appeared first on drmolander.com.